Trial Profile
A retrospective chart review to evaluate safety and efficacy of gemcitabin , cisplatin and bevacizumab combination therapy for patients with ovarian clear cell carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results (n=6), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology